CCND1 and ovarian carcinoma: This is consistent with the findings of Lengyel et al. [45], who demonstrated that MET inhibited ovarian cancer progression in animal models by halting the cell cycle at G0/G1 that was associated with a reduction in cyclin D1 levels.